Kar Sidhartha S, Bhat G Varadaraj, Rao Praveen Pn, Shenoy Vishnu P, Bairy Indira, Shenoy G Gautham
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India.
School of Pharmacy, Health Sciences Campus, University of Waterloo, Waterloo, ON, Canada.
Drug Des Devel Ther. 2016 Jul 18;10:2299-310. doi: 10.2147/DDDT.S104037. eCollection 2016.
A series of triclosan mimic diphenyl ether derivatives have been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv. The binding mode of the compounds at the active site of enoyl-acyl carrier protein reductase of M. tuberculosis has been explored. Among them, compound 10b was found to possess antitubercular activity (minimum inhibitory concentration =12.5 µg/mL) comparable to triclosan. All the synthesized compounds exhibited low levels of cytotoxicity against Vero and HepG2 cell lines, and three compounds 10a, 10b, and 10c had a selectivity index more than 10. Compound 10b was also evaluated for log P, pKa, human liver microsomal stability, and % protein binding, in order to probe its druglikeness. Based on the antitubercular activity and druglikeness profile, it may be concluded that compound 10b could be a lead for future development of antitubercular drugs.
已合成了一系列三氯生类似物二苯醚衍生物,并对其针对结核分枝杆菌H37Rv的体外抗结核活性进行了评估。已探究了这些化合物在结核分枝杆菌烯酰 - 酰基载体蛋白还原酶活性位点的结合模式。其中,发现化合物10b具有与三氯生相当的抗结核活性(最低抑菌浓度 = 12.5 µg/mL)。所有合成的化合物对Vero和HepG2细胞系均表现出低水平的细胞毒性,并且三种化合物10a、10b和10c的选择性指数大于10。还对化合物10b的脂水分配系数、酸度系数、人肝微粒体稳定性和蛋白结合率进行了评估,以探究其类药性质。基于抗结核活性和类药性质概况,可以得出结论,化合物10b可能是未来抗结核药物开发的先导化合物。